1. In a key change, the Global Initiative for Asthma (GINA) Strategy 2021 Report divided asthma treatment for adults and adolescents into how many tracks?
Answer: A. 2 tracks are now recommended by GINA for treatment of asthma in adolescents and adults.
2. True or False: The updated GINA Strategy 2021 Report recommends add-on long-acting muscarinic antagonists (LAMAs) and azithromycin for patients with severe asthma.
Answer: B. False. The updated GINA Strategy 2021 Report recommends add-on biologic therapies for patients with severe asthma.
3. Which of the above were identified as clinical characteristics and biomarkers associated with elevated exacerbation risk in severe, uncontrolled asthma?
Answer: A. Exacerbation history, B. Maintenance corticosteroid use, and C. Nasal polyposis were associated with elevated exacerbation risk in severe, uncontrolled asthma.
4. In the PONENTE trial, the use of a rapid, individualized steroid-reduction algorithm achieved which result in a majority of patients with severe eosinophilic asthma?
Answer: C. Elimination or maximal reduction of OCS was seen using a rapid, individualized steroid reduction algorithm.
5. A recent study showed that patients with severe asthma are most likely to follow a recommendation from their health care provider to do which of the above?
Answer: C. To remain on treatment. Patients with severe asthma were more likely to adhere to advice to remain on treatment vs to reduce or increase it.
6. In a recent survey, what percentage of patients with severe asthma underestimated their disease severity?
Answer: D. 95% of patients with severe asthma underestimated the severity of their disease.
7. Which of the above were found to be significant risk factors for accelerating time to COPD incidence in patients with asthma?
Answer: B. Older age and C. History of tobacco use were signficant risk factors for accelerating to COPD but A. Female sex was not.
8. True or False: More severe asthma is associated with more severe COVID-19.
Answer: A. True. Significantly associated with hospitalization were asthma with regular ICS use, intermittent ICS plus add-on asthma medication use, regular ICS plus add-on use, and frequent exacerbations.